Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries. November 22 ...
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...
Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...
Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), on Boehringer pipeline targets enabled by the Salipro®-technology to identify ...